Nexturn Bio Inc Decided To Invest In The Development Of A New Drug Pipeline For Diabetes Treatment Using MiRNA

SEOUL, South Korea, May 6, 2021 /PRNewswire/ -- Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd. (KOSDAQ:89140), said it has secured a 50% stake in RosVivo Therapeutics Inc., a U.S. new drug developer, as its first investment destination. RosVivo recently developed RSVI-301, a new drug pipeline that utilizes miRNA (MicroRNA), which is expected to be the next-generation drug, following mRNA (Messenger RNA), which has attracted attention as a Covid-19 vaccine. Unlike rare diseases or cancer, targeting chronic disease "diabetes," seems to have positively affected Nexturn Bio's investment. According to data released by the WHO in April this year, the number of diabetes patients worldwide is about 420 million, which has maintained a high prevalence rate until recently. The figure of the patients proves that diabetes drugs currently developed up to the fourth generation are not as effective as expected. In fact, Liraglutide, which are known to be the most effective component of diabetes drugs ever approved by the FDA, have also reported vomiting, diarrhea, constipation and indigestion as side effects from the clinical stages. The side effect reduction of RSVI-301 is more noticeable in the table below, compiled according to the research paper provided by RosVivo. (figure 1). Furthermore, it has been observed that RSVI-301 reduces insulin resistance by normal levels during repeated drug infusions (figure 2). With the result of being completely opposite to the existing diabetes drugs, the possibility of overcoming insulin resistance raises RSVI-301 expectations in the related industry. The low side effects and the long-term lasting effects of RSVI-301 are expected to play a major competitive role in the future diabetes market in regard to patient convenience. An official from Nexturn Bio Inc. added, "We will continue to provide generous support for RosVivo's development of new drugs as well as to cure diabetes together

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!